T1	Treatment 31 52	entecavir prophylaxis
T2	Treatment 182 203	antiviral prophylaxis
T3	Treatment 262 290	rituximab-based chemotherapy
T4	Treatment 479 771	prophylactic entecavir (ETV) before chemotherapy to 3 months after completing chemotherapy (ETV prophylactic group, n = 41) or to receive therapeutic ETV at the time of HBV reactivation and hepatitis B surface antigen (HBsAg) reverse seroconversion since chemotherapy (control group, n = 39).
T5	Treatment 977 980	ETV
T6	Treatment 1848 1869	Antiviral prophylaxis
